Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -1.77 is 767% below its 5-year average of -0.20, around the middle of its 5-year range (-6.31–3.04).
As of the fiscal period ended Tuesday, June 30, 2026. 60.08% below its 12-month average of -1.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q3 FY2026 (2026-06-30): -1.77.
DEBT TO EQUITY RATIO
-1.77
DEBT TO EQUITY RATIO AVG TTM
-1.11
DEBT TO EQUITY RATIO AVG 3Y
-1.02
DEBT TO EQUITY RATIO AVG 5Y
-0.20
DEBT TO EQUITY RATIO AVG 10Y
-0.52
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-60.08%
CURRENT VS 3Y AVG
-73.33%
CURRENT VS 5Y AVG
-767.40%
CURRENT VS 10Y AVG
-240.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-1712.27%
vs the sector median at left
Outlook Therapeutics, Inc.
Market Cap
$107.73M
Debt to Equity Ratio
-1.77
TTM Avg
-1.11
3Y Avg
-1.02
5Y Avg
-0.20
Market Cap
$107.79M
Debt to Equity Ratio
0.94
TTM Avg
1.15
3Y Avg
0.83
5Y Avg
0.89
Market Cap
$107.89M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$105.99M
Debt to Equity Ratio
0.04
TTM Avg
0.01
3Y Avg
0.26
5Y Avg
0.35
Market Cap
$109.49M
Debt to Equity Ratio
3.72
TTM Avg
2.72
3Y Avg
1.72
5Y Avg
1.15
Market Cap
$105.63M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
Market Cap
$110.43M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$104.67M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.03
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $107.73M | -1.77 | -1.11 | -1.02 | -0.20 |
| Vivani Medical, Inc. (VANI)vs › | $107.79M | 0.94 | 1.15 | 0.83 | 0.89 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $107.89M | 0.01 | 0.00 | 0.00 | 0.00 |
| Immunic, Inc. (IMUX)vs › | $106.11M | 0.00 | 0.05 | 0.03 | 0.02 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.99M | 0.04 | 0.01 | 0.26 | 0.35 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 3.72 | 2.72 | 1.72 | 1.15 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $105.63M | 0.27 | 0.66 | 0.63 | 0.55 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.43M | N/A | 0.12 | 0.14 | 0.21 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.67M | 0.00 | 0.00 | 0.03 | 0.03 |
| Definitive Healthcare Corp. (DH)vs › | $104.03M | 1.15 | 0.59 | 0.44 | 0.41 |
Debt/Equity
-1.77
Current Ratio
0.81
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -1.77 |
| 2026-03-31 | -0.94 |
| 2025-12-31 | -0.96 |
| 2025-09-30 | -0.94 |
| 2025-06-30 | -0.93 |
| 2025-03-31 | -1.03 |
| 2024-12-31 | -0.62 |
| 2024-09-30 | -0.41 |
| 2024-06-30 | -0.39 |
| 2024-03-31 | -0.33 |
| 2023-12-31 | -1.50 |
| 2023-09-30 | -2.46 |
| 2023-06-30 | -6.31 |
| 2023-03-31 | 3.04 |
| 2022-12-31 | 2.02 |
| 2022-09-30 | 1.25 |
| 2022-06-30 | 0.52 |
| 2022-03-31 | 0.64 |
| 2021-12-31 | 0.46 |
| 2021-09-30 | 2.58 |
| 2021-06-30 | 0.92 |
| 2021-03-31 | 0.55 |
| 2020-12-31 | -1.08 |
| 2020-09-30 | 3.11 |
| 2020-06-30 | 0.81 |
| 2020-03-31 | -0.90 |
| 2019-12-31 | -0.57 |
| 2019-09-30 | -1.39 |
| 2019-06-30 | -11.03 |
| 2019-03-31 | -0.58 |
| 2018-12-31 | -0.84 |
| 2018-09-30 | -1.07 |
| 2018-06-30 | -2.36 |
| 2018-03-31 | -1.42 |
| 2017-12-31 | -2.18 |
| 2017-09-30 | -0.60 |
| 2017-06-30 | -0.59 |
| 2017-03-31 | -0.46 |
| 2016-12-31 | -0.50 |
| 2016-09-30 | -1.68 |
| 2016-06-30 | 5.91 |
| 2016-03-31 | -0.72 |
| 2015-12-31 | -1.29 |
| 2015-09-30 | -0.64 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
